Controlled Trial of Sulpiride in Chronic Schizophrenic Patients

Authors:
  • JEJ. Guy Edwards
    J. Guy Edwards
  • JAJohn R. Alexander
    John R. Alexander
  • MAM. S. Alexander
    M. S. Alexander
  • AGAlan Gordon
    Alan Gordon
  • TZT. Zutchi
    T. Zutchi

Abstract
Summary: In a double-blind comparative trial of sulpiride (600–1,800 mg/day) and trifluoperazine (15–45 mg/day) in 38 chronic schizophrenic patients, ratings of therapeutic results and unwanted effects were made at two-weekly interviews during the six weeks treatment period. The results show that sulpiride has neuroleptic properties and a spectrum of therapeutic activity similar to that of trifluoperazine. There was an association between plasma sulpiride levels and therapeutic response after four weeks' treatment.

This publication has 13 references indexed in Scilit: